BWXT's Government business drives profit growth

BWX Technologies earned more from Government Operations in the third quarter even as Commercial Operations supplied the larger revenue increase. Government operating income rose $25.2 million on a $22.4 million revenue increase.¹

The distinction matters for the earnings outlook: Government generated more profit from modest sales growth, while Commercial added sales through both an acquisition and existing operations.^1,2 Quarterly cash generation strengthened too, helped by higher net income, advance billings and working-capital management; income-tax payment timing partly offset those benefits.¹

Government turns modest sales growth into more profit

Government revenue grew 3.6% from a year earlier. BWXT attributed the increase to special materials and advanced nuclear, partly offset by lower naval propulsion volume.¹ The filing also identified growth associated with Aerojet Ordnance Tennessee and enrichment operations; Aerojet Ordnance Tennessee was already included in both third-quarter periods.²

Government’s GAAP operating margin reached 19.2%, up from 15.8% a year earlier.¹ BWXT attributed the operating-income increase primarily to the revenue changes and integration expenses that had affected the prior-year period.²

Cost of operations plus selling, general and administrative expenses rose just $265 thousand in Government Operations.² Higher equity income from investees contributed $4.0 million, accounting for 15.8% of the segment’s operating-income increase.^1,2

Company-wide net favorable contract-estimate changes added $3.6 million to operating income, or 2.8% of the total.^1,2 That benefit was only $0.6 million larger than a year earlier.² The disclosed company-wide estimate changes therefore account for little of the quarterly profit improvement.^1,2

The nine-month comparison has a different starting point: Government’s 2025 results included a $29.4 million favorable adjustment on a nuclear operations contract.²

Higher corporate expenses absorbed part of the segment gains: unallocated corporate expense reached $16.8 million, compared with $8.0 million a year earlier.¹ BWXT attributed the increase mainly to restructuring and transformation spending, merger-related legal and consulting costs, and healthcare claim timing.²

Commercial growth extends beyond the acquisition

Commercial revenue rose 25.2% from a year earlier.¹ Precision Components Group, acquired in July, supplied part of that increase; inspection, maintenance, modification and refurbishment work also contributed.²

Excluding only PCG’s stated contribution, Commercial revenue grew 14.7%, by our calculation; Medical remains in both periods.^1,2 Kinectrics, acquired in May 2025, was already included in both third-quarter periods.²

Commercial adjusted EBITDA grew 16.6%, slower than revenue. BWXT attributed the pressure on non-GAAP operating-income growth to product and service mix and investment in selling, general and administrative functions.¹ The filing also identified higher acquisition and restructuring expenses as a drag on GAAP operating-income growth.²

Commercial’s GAAP operating margin fell to 8.4% from 9.5%.¹ That segment-wide margin combines PCG with the rest of Commercial Operations.^1,2

Quarterly bookings fall short of sales; the longer window holds up

BWXT booked 0.56 dollars of new business for each dollar of revenue in Q3. Both Government and Commercial bookings were below their respective quarterly revenues.¹ The year-earlier comparison includes large, multi-year special materials projects that BWXT identified as a driver of its backlog.⁶

Across the four quarters ended September 30, bookings totaled $4.19 billion against $3.60 billion of revenue. That produces a book-to-bill ratio of 1.16, a less abrupt picture than the single-quarter result.^1,3,4,5

BWXT describes major new U.S. Government awards as typically following congressional approval of the next fiscal year’s budget.² President and Chief Executive Officer Rex D. Geveden said BWXT expects increased conversion of its bid pipeline into firm awards through the rest of 2026 and into 2027.¹

Total backlog reached $8.56 billion, up 15.8% from a year earlier and 1.9% from June. The quarterly increase needs to be read alongside the segment movements.^1,4

Government backlog fell $315.8 million during Q3, while Commercial backlog rose $473.9 million. Commercial’s reported ending balance exceeds June backlog plus Q3 bookings minus Q3 revenue by $572.9 million. This roll-forward leaves that difference unallocated.^1,4

The total includes $1.97 billion of unfunded U.S. Government backlog.² On a net-balance basis, unfunded backlog fell $285.5 million since June, while backlog excluding those unfunded amounts increased $443.6 million.^2,7

BWXT expects to recognize approximately 46% of September backlog as revenue by the end of 2027.² Its June estimate was approximately 55% through the same end date; the later estimate starts one quarter later.^2,7 Backlog excludes unconsolidated joint-venture contracts and approximately $1.4 billion of unexercised options.²

Cash generation benefits from payment and billing timing

Quarterly operating cash flow reached $202.7 million. BWXT attributed the improvement to higher net income, advance billings and working-capital management, partly offset by income-tax payment timing. Capital spending also increased, which BWXT attributed to the timing of growth projects, primarily in Commercial Operations.¹

For the first nine months, operating cash flow increased $98.9 million from the comparable 2025 period.¹ BWXT attributed the increase primarily to favorable timing of vendor payments, customer billings and project cash flows, together with higher net income. Lower income taxes payable partly offset those benefits.²

The accounts-payable change contributed $150.3 million to nine-month operating cash flow, approximately one-third of the total.¹ That timing contribution limits how much of the cash improvement can be treated as a recurring earnings benefit.^1,2 The nine-month cash flow statement reports no amount on its repurchases of common stock line.¹

At September 30, BWXT held $568.5 million of cash against $2.02 billion of long-term debt at carrying value.¹ Its revolver was undrawn, with $1.25 billion available. The capital structure includes $1.25 billion of 0% convertible senior notes due 2030, issued in November 2025.²

Quarterly interest expense fell $8.9 million to $5.1 million. The release attributed non-GAAP EPS growth partly to lower interest expense and a lower effective tax rate, alongside higher non-GAAP operating income. Lower other income partly offset those gains.¹

The release’s prior-year non-GAAP tax-rate row is internally inconsistent: it prints 20.0%, while its tax and pretax amounts imply 23.6%. The corresponding Q3 2026 calculation is 22.2%, supporting the release’s description of a lower rate when calculated on that basis.¹

Guidance implies more fourth-quarter earnings, less cash than last year

November’s guidance update narrowed the non-GAAP EPS range, raised the free-cash-flow floor and set adjusted EBITDA at the midpoint of the prior range.^1,4 Revenue guidance was reaffirmed.¹

The full-year progression includes an acquisition-related scope change: May guidance excluded PCG, while August guidance included its contribution. August guidance covers a broader set of businesses than May’s.^4,5

Subtracting nine-month results from the current full-year outlook implies fourth-quarter revenue above both Q3 2026 and Q4 2025.^1,2,3 Implied adjusted EBITDA is above Q4 2025 and roughly in line with Q3 2026, allowing for rounded guidance. The implied free cash flow is below the year-earlier fourth quarter.^1,3,4,5

The cash arithmetic calls for restraint in extending Q3’s performance into year-end.^1,4,5

The portfolio changes the base for the next year

BWXT acquired PCG for approximately $216.8 million in July. BWXT says the acquisition expands its heavy-manufacturing footprint and adds U.S. commercial nuclear production capacity.² The acquisition cash flow shown above is net of cash acquired and is a separate measure from the stated transaction price.^1,2

BWXT also agreed in July to sell its medical business to Nordic Capital in a transaction valued at up to $800 million. The transaction is subject to regulatory approvals and is expected to close in 2026 or the first quarter of 2027. BWXT will retain a minority interest and continue providing specialized isotope and radiochemical expertise.²

BWXT classified the medical business, part of Commercial Operations, as held for sale at September 30, 2026. It remains in reported continuing segment results.^1,2 At Investor Day, BWXT said the midpoint of its 2026 guidance included approximately $130 million of Medical revenue.⁸ BWXT described the sale as enabling greater focus on nuclear national defense and commercial nuclear power.⁴

For 2027, BWXT’s preliminary outlook calls for high-single-digit revenue growth and high-single-digit to low-double-digit growth in adjusted EBITDA and non-GAAP EPS.¹ September’s Investor Day framework assumed a year-end Medical sale.⁸ The filing’s expected closing window extends into the first quarter of 2027, leaving the timing relevant to the consolidated revenue base.^1,2

BWXT’s Janus selection carries a longer delivery horizon

BWXT’s Advanced Nuclear Reactor technology was selected for the Army’s Janus Program at Fort Campbell and for Prodigy Clean Energy’s transportable nuclear power plant project in Canada.¹ BWXT’s Investor Day presentation said the Janus Program targets site groundbreaking in 2028 and operations in the early 2030s.⁸